Depression is a common mental illness and leading cause of disability. Most current antidepressants are associated with significant limitations, and in particular, a delayed onset and low rate of efficacy. Consequently, there remains an ongoing need for antidepressants that are either more effective or better tolerated than existing standards. We previously identified ZY-1408 as a drug with a novel chemical structure and potential anti-depressant-like activity. Specifically, ZY-1408 is a novel serotonin 2C (5-HT) receptor antagonist and serotonin/norepinephrine (5-HT/NE) reuptake inhibitor. In this study, we further investigated the antidepressant-like efficacy of ZY-1408 using in vitro and in vivo behavioral tests. ZY-1408 showed 5-HT receptor antagonist and 5-HT/NE reuptake inhibitor properties in vitro. Meanwhile, ZY-1408 decreased immobility in vivo in a dose-dependent manner in rats (via the forced-swim test) and mice (via the tail-suspension test). The behavioral test results do not appear to result from stimulation of locomotor activity. In chronically stressed rats, repeated ZY-1408 treatment significantly reversed depressive-like behavior, including reduced sucrose preference, decreased locomotor activity, and prolonged time to begin eating. Furthermore, in vivo microdialysis showed that administration of ZY-1408 significantly increased extracellular concentrations of 5-HT and NE in the hippocampus of freely moving rats. Thus, ZY-1408 is a potent and orally active 5-HT receptor antagonist and 5-HT/NE reuptake inhibitor with antidepressant-like activity in rodents.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.neuropharm.2020.108376 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mood Alterations in the Prodromal Phase of Sporadic Creutzfeldt-Jakob Disease.
JAMA Neurol
December 2024
Department of Neurology, Medical University of Vienna, Vienna, Austria.
Importance: Sporadic Creutzfeldt-Jakob disease (sCJD) is a rare, rapidly progressive and fatal neurodegenerative disease. Definite sCJD diagnosis can only be made post mortem, and little is known about the prodromal phase of the disease.
Objective: To compare drug prescription patterns before the clinical onset of sCJD between patients and matched controls for exploration of potential risk factors and to assess correlations between drug exposure and sCJD survival.
Drug Development.
Alzheimers Dement
December 2024
School of Medicine, Johns Hopkins University, and Johns Hopkins Bayview Medical Center, Baltimore, MD, USA.
Background: Agitation is a common and disabling symptom of Alzheimer's dementia (AD). Pharmacological treatments are recommended if agitation is not responsive to psychosocial intervention. Citalopram was effective in treating agitation in AD but was associated with cognitive and cardiac risks linked to its R- but not S-enantiomer.
View Article and Find Full Text PDFVulvodynia - A contemporary understanding and practical approach in primary care settings.
Malays Fam Physician
December 2024
MCGP, FRCOG, Department of Obstetrics and Gynaecology, IMU University, Clinical Campus, Jalan Rasah, Bukit Rasah, Seremban, Negeri Sembilan, Malaysia.
Vulvodynia manifests as persistent vulvar pain, affecting both sexual well-being and overall quality of life. While the precise cause remains elusive, various multifaceted predisposing and precipitating factors have been identified. Neurobiological and psychosocial elements contribute to a better understanding of the management of this complex disorder.
View Article and Find Full Text PDFMacronutrients in Human Milk Exposed to Antidepressant and Anti-Inflammatory Medications.
JAMA Netw Open
January 2025
Department of Pediatrics, Center for Better Beginnings, University of California, San Diego, La Jolla.
Importance: The association between maternal medications and the macronutrient composition of human milk has not been studied.
Objective: To compare macronutrient levels in milk samples from mothers treated with long-term medications with samples from untreated healthy and disease-matched control mothers (DMCs).
Design, Setting, And Participants: A cross-sectional study using samples collected between October 2014 and January 2024 from breastfeeding mothers in the US and Canada invited to participate to the Mommy's Milk Human Milk Research Biorepository at the University of California, San Diego.
Contemporary Perspectives in Critical Care of Neuroleptic Malignant Syndrome.
Neurocrit Care
January 2025
Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA.
Background: Neuroleptic malignant syndrome (NMS) is a psychiatric-neurologic emergency that may require intensive care management. There is a paucity of information about NMS as a critical illness. We reviewed the Mayo Clinic experience.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!